Head to Head Contrast: Nicox (OTCMKTS:NICXF) versus Janux Therapeutics (NASDAQ:JANX)

Janux Therapeutics (NASDAQ:JANX) and Nicox (OTCMKTS:NICXF) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, earnings and valuation.

Earnings & Valuation

This table compares Janux Therapeutics and Nicox”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10.00 million	88.30	-$113.62 million	($1.84)	-7.87
Nicox	$3.59 million	5.76	-$24.23 million	N/A	N/A

Nicox has lower revenue, but higher earnings than Janux Therapeutics.

Volatility & Risk

Janux Therapeutics has a beta of 2.58, indicating that its stock price is 158% more volatile than the S&P 500. Comparatively, Nicox has a beta of -0.04, indicating that its stock price is 104% less volatile than the S&P 500.

Profitability

This table compares Janux Therapeutics and Nicox’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-12.93%	-12.23%
Nicox	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Janux Therapeutics and Nicox, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2	3	9	1	2.60
Nicox	0	1	1	0	2.50

Janux Therapeutics presently has a consensus price target of $45.85, indicating a potential upside of 216.62%. Given Janux Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Janux Therapeutics is more favorable than Nicox.

Insider & Institutional Ownership

75.4% of Janux Therapeutics shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Janux Therapeutics beats Nicox on 9 of the 12 factors compared between the two stocks.

About Janux Therapeutics

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

About Nicox

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France.